Familial hypercholesterolaemia: identification and management

National Institute for Health and Care Excellence

The prevalence of heterozygous familial hypercholesterolaemia (FH) in the UK population is estimated to be 1 in 500, which means that approximately 110,000 people are affected. The elevated serum cholesterol concentration that characterises heterozygous FH leads to a greater than 50% risk of coronary heart disease in men by the age of 50 years, and at least 30% in women by the age of 60 years, if left untreated.

This Guidelines summary covers diagnosis, identifying people with FH using cascade testing, and management

Register to view this page

Log in or register now for FREE in order to:

  • benefit from unlimited access to all pages, including:
    • 180+ guideline summaries
    • 1000+ evidence-based articles
  • review and leave comments on all articles and summaries
  • automatically track your reading and learning via your CPD tracker
  • on-demand webinars presented by leading clinical experts

Registration only takes 2 minutes and it will give you FREE access to all content across:

  • GuidelinesinPractice.co.uk
  • Guidelines.co.uk
  • GuidelinesforNurses.co.uk


Log in

Need help? Email us